Clinical-stage biotech developing proprietary IV-infused psilocin and synthetic oral psilocybin formulations combined with psychotherapy to treat disorders with unmet needs such as binge eating disorder, fibromyalgia, and IBS-related abdominal pain. IV-infused psilocin aims to shorten time-to-onset, control depth/duration of the psychedelic experience, and reduce intervention duration versus oral psilocybin; oral formulation showed >80% average reduction in binge episodes in early trials.